Veru Inc.

Veru was featured in The Athletic, a New York Times company, in an article examining GLP-1s, muscle loss, and the evolving debate around performance enhancement in sports.

The article highlights a key issue in GLP-1 weight loss: muscle loss. Veru is working to address this clinical challenge through enobosarm as an adjunctive therapy with GLP-1 drugs to help preserve lean muscle.

Veru’s CEO, Dr. Mitchell Steiner, was quoted in the article discussing enobosarm.

Serena Williams and the coming reckoning with GLP-1s and performance enhancement GLP-1s are not prohibited; the way they work means they might never be. Anti-doping authorities are still monitoring how athletes use them.